EcoR1 Capital, LLC: CRINETICS PHARMACEUTICALS IN (CRNX): Quarterly 13F Position History
As of Q1 2026, EcoR1 Capital, LLC reported 4,288,120 shares of CRINETICS PHARMACEUTICALS IN (CRNX), worth $155.7M and representing 6.7% of its 13F equity book. The position first appeared in Q1 2020 and has been disclosed across 25 13F-HR filings in Pactolio's tracked window.
- 4,288,120Shares Held (Latest Filing)
- $155.7MReported Market Value (Latest Filing)
- 6.7%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$43.9MQuarter-over-Quarter Value Change
- 4,288,120Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 25 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,288,120 | 0 | — | $155.7M | 6.7% | $36.3 |
| Q4 2025 | 4,288,120 | 0 | — | $199.6M | 9.1% | $46.5 |
| Q3 2025 | 4,288,120 | 0 | — | $178.6M | 8.6% | $41.6 |
| Q2 2025 | 4,288,120 | 0 | — | $123.3M | 7.3% | $28.8 |
| Q1 2025 | 4,288,120 | 0 | — | $143.8M | 8.5% | $33.5 |
| Q4 2024 | 4,288,120 | 0 | — | $219.3M | 8.8% | $51.1 |
| Q3 2024 | 4,288,120 | +132,745 | +3.2% | $219.1M | 7.5% | $51.1 |
| Q2 2024 | 4,155,375 | 0 | — | $186.1M | 5.7% | $44.8 |
| Q1 2024 | 4,155,375 | +2,142,858 | +106.5% | $194.5M | 4.9% | $46.8 |
| Q4 2023 | 2,012,517 | +482,254 | +31.5% | $71.6M | 1.9% | $35.6 |
| Q3 2023 | 1,530,263 | +200,000 | +15.0% | $45.5M | 1.6% | $29.7 |
| Q2 2023 | 1,330,263 | 0 | — | $24.0M | 0.6% | $18.0 |
| Q1 2023 | 1,330,263 | 0 | — | $21.4M | 0.7% | $16.1 |
| Q4 2022 | 1,330,263 | 0 | — | $24.3M | 0.7% | $18.3 |
| Q3 2022 | 1,330,263 | 0 | — | $26.1M | 0.8% | $19.6 |
| Q2 2022 | 1,330,263 | +540,054 | +68.3% | $24.8M | 0.9% | $18.6 |
| Q1 2022 | 790,209 | +200,040 | +33.9% | $17.3M | 0.5% | $21.9 |
| Q4 2021 | 590,169 | +590,169 | — | $16.8M | 0.5% | $28.4 |
| Q3 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2020 | 0 | 859,802 | -100.0% | $0 | 0.0% | — |
| Q2 2020 | 859,802 | +509,802 | +145.7% | $15.1M | 1.1% | $17.5 |
| Q1 2020 | 350,000 | — | — | $5.1M | 0.5% | $14.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did EcoR1 Capital, LLC first disclose a CRNX position in 13F-HR filings?
EcoR1 Capital, LLC first reported CRINETICS PHARMACEUTICALS IN (CRNX) on its 13F-HR filing for the period ending 2020-03-31 (Q1 2020). The position has appeared on 25 reported quarters within Pactolio's tracked window.
What was EcoR1 Capital, LLC's most recent quarter-over-quarter share-count change in CRNX?
EcoR1 Capital, LLC held the same 4,288,120 shares of CRNX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent EcoR1 Capital, LLC's cost basis in CRNX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.